A Study of LY3532226 in Participants With Obesity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

132 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-16

Study Completion Date

2025-12-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity. Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it following weekly or monthly administration. Part A of the study will last approximately 16 weeks, excluding screening period. Part B of the study will last approximately 20 weeks, excluding the screening period. Part C of the study will last approximately 8 weeks, excluding the screening period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT07225556

Overweight Obesity

RECRUITING PHASE1

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06230523

Obesity Overweight and Obesity

COMPLETED PHASE2

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

NCT06606106

Overweight Obesity

ACTIVE_NOT_RECRUITING PHASE1

A Study of LY3841136 in Healthy and Overweight Participants

NCT05295940

Obesity Healthy

COMPLETED PHASE1

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06683508

Obesity Overweight

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3532226 (Part A)

LY3532226 administered subcutaneously (SC)

Group Type EXPERIMENTAL

LY3532226

Intervention Type DRUG

Administered SC

Placebo (Part A)

Placebo administered SC

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC

LY3532226 (Part B)

LY3532226 administered SC

Group Type EXPERIMENTAL

LY3532226

Intervention Type DRUG

Administered SC

Placebo (Part B)

Placebo administered SC

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC

LY3532226 (Part C)

LY3532226 administered SC

Group Type EXPERIMENTAL

LY3532226

Intervention Type DRUG

Administered SC

Placebo (Part C)

Placebo administered SC

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3532226

Administered SC

Intervention Type DRUG

Placebo

Administered SC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a body weight not exceeding 150 kilograms (kg) or 330 pounds (lb) and body mass index (BMI) within the range of 30 to 40 kilogram per square meter (kg/m²)
* Have had a stable body weight that is less than or equal to 5% change in body weight for 3 months prior to screening and enrollment

Exclusion Criteria

* Have a lifetime history of a suicide attempt
* Have a history or presence of psychiatric disorders, including a history of major depressive disorder within the last 2 years
* Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater, and/or a score of 2 or greater for either of the first 2 questions on the PHQ-9 questionnaire
* Have a known clinically significant gastric emptying abnormality, have undergone gastric bypass surgery or restrictive bariatric surgery
* Have taken approved or investigational medication for weight loss, within the previous 3 months or 5 half-lives of study screening, whichever is earlier
* Intend to use any weight-loss medications during study participation
* Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No